SG11202109112WA - Fragile x mental retardation protein interfering oligonucleotides and methods of using same - Google Patents

Fragile x mental retardation protein interfering oligonucleotides and methods of using same

Info

Publication number
SG11202109112WA
SG11202109112WA SG11202109112WA SG11202109112WA SG11202109112WA SG 11202109112W A SG11202109112W A SG 11202109112WA SG 11202109112W A SG11202109112W A SG 11202109112WA SG 11202109112W A SG11202109112W A SG 11202109112WA SG 11202109112W A SG11202109112W A SG 11202109112WA
Authority
SG
Singapore
Prior art keywords
fragile
methods
same
mental retardation
retardation protein
Prior art date
Application number
SG11202109112WA
Other languages
English (en)
Inventor
Francesca Viti
Salvatore Bellinvia
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of SG11202109112WA publication Critical patent/SG11202109112WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202109112WA 2019-02-26 2020-02-26 Fragile x mental retardation protein interfering oligonucleotides and methods of using same SG11202109112WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810697P 2019-02-26 2019-02-26
PCT/EP2020/055071 WO2020174023A1 (en) 2019-02-26 2020-02-26 Fragile x mental retardation protein interfering oligonucleotides and methods of using same

Publications (1)

Publication Number Publication Date
SG11202109112WA true SG11202109112WA (en) 2021-09-29

Family

ID=69723929

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109112WA SG11202109112WA (en) 2019-02-26 2020-02-26 Fragile x mental retardation protein interfering oligonucleotides and methods of using same

Country Status (12)

Country Link
US (1) US20220145303A1 (zh)
EP (1) EP3931324A1 (zh)
JP (1) JP2022521502A (zh)
KR (1) KR20210132678A (zh)
CN (1) CN113748207A (zh)
AU (1) AU2020228134A1 (zh)
BR (1) BR112021016907A2 (zh)
CA (1) CA3130854A1 (zh)
EA (1) EA202192330A1 (zh)
MX (1) MX2021010255A (zh)
SG (1) SG11202109112WA (zh)
WO (1) WO2020174023A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122800A1 (en) * 2021-12-23 2023-06-29 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009315898B2 (en) 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
EP2411532B1 (en) * 2009-03-24 2017-04-05 Asuragen, Inc. Pcr methods for characterizing the 5' untranslated region of the fmr1 and fmr2 genes
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
US20130149297A1 (en) * 2010-07-02 2013-06-13 Vib Vzw Role of fragile x mental retardation gene and protein in cancer metastasis
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
JP2018528968A (ja) * 2015-09-17 2018-10-04 ユニバーシティ オブ マサチューセッツ Ｆｍｒ１発現を調節するための組成物および方法
EP3368089A4 (en) * 2015-10-26 2019-05-29 Translate Bio Ma, Inc. NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF NUCLEIC ACID COMPLEXES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122800A1 (en) * 2021-12-23 2023-06-29 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Also Published As

Publication number Publication date
CN113748207A (zh) 2021-12-03
CA3130854A1 (en) 2020-09-03
AU2020228134A1 (en) 2021-10-14
BR112021016907A2 (pt) 2021-11-03
EP3931324A1 (en) 2022-01-05
EA202192330A1 (ru) 2021-12-13
MX2021010255A (es) 2021-12-15
JP2022521502A (ja) 2022-04-08
KR20210132678A (ko) 2021-11-04
WO2020174023A1 (en) 2020-09-03
US20220145303A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
EP3743063A4 (en) CBL-B INHIBITORS AND METHOD OF USING THEREOF
EP3914259A4 (en) RNA EDITING OLIGONUCLEOTIDES AND THEIR USES
EP3914261A4 (en) Rna-editing oligonucleotides and uses thereof
EP3914260A4 (en) RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
EP3823775A4 (en) ARTICLES AND MANUFACTURING PROCESSES
IL289813A (en) Antibody against tau and its use
IL285853A (en) Testing device and method for using it
EP4022069A4 (en) MODIFIED CIRCULAR RNAS AND METHOD OF USE THEREOF
EP3899223A4 (en) CATALYTIC ARTICLE AND PROCESS OF MAKING AND USE THEREOF
IL285746A (en) High-affinity anti-mertek antibodies used
PL3711730T3 (pl) Wyroby chłonne i sposoby wytwarzania
IL288259A (en) Modified Gapmer Oligonucleotides and Methods of Use
EP3570940A4 (en) USE OF PRIDOPIDINE TO TREAT THE FRAGILE X SYNDROME
EP3891175A4 (en) MODIFIED PROTEINS AND RELATED TREATMENT METHODS
IL274363B1 (en) Use of a specific anti-protein siRNA for the treatment of hemophilia
EP3966328A4 (en) ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
EP3755148A4 (en) SALSALATE NANOSUSPENSIONS AND THEIR PROCESSES FOR USE
IL286485A (en) pi4-kinase inhibitors and methods of using them
EP3714053A4 (en) CHEMICAL-DEPENDENT PROBE EVALUATION OF PROTEIN ACTIVITY AND ITS USES
SG11202109112WA (en) Fragile x mental retardation protein interfering oligonucleotides and methods of using same
IL284475A (en) Multiple value test and methods for using it
EP3649240A4 (en) RNAI ALPHA-ENaC GENE EXPRESSION INHIBITION AGENTS AND METHODS OF USE
EP4101379C0 (en) BIOSENSOR CAPSULE AND SYSTEM
EP3775172A4 (en) Splice-switching oligonucleotides and methods of use
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof